Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Digestive System Neoplasms 3Digestive System Diseases 3Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Urogenital Neoplasms 1Stomach Neoplasms 1Stomach Diseases 1Rectal Diseases 1Pancreatic Neoplasms 1Pancreatic Diseases 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Intestinal Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Gonadal Disorders 1Genital Neoplasms, Female 1Genital Diseases, Female 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Esophageal Neoplasms 1Esophageal Diseases 1Colorectal Neoplasms 1Colonic Diseases 1Carcinoma 1Breast Neoplasms 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × Ocoxin × Clear all
NCT03559543 2024-02-07

Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Catalysis SL

Phase 2 Completed
40 enrolled
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡